Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].

Bulletin du cancer - 1 Oct 2015

Schreiber Valérie, Illuzzi Giuditta, Héberlé Eléa, Dantzer Françoise

Abstract excerpt

Poly(ADP-ribosyl)ation is a post-translational modification catalyzed by poly(ADP-ribose) polymerases. PARP-1 is a molecular sensor of DNA breaks, playing a key role in the spatial and temporal organization of their repair, contributing to the maintenance of genome integrity and cell survival. The fact that PARP inhibition impairs efficacy of break repair has been exploited as anticancer strategies to potentiate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials, Phase III as Topic
Share to DNA Breaks, Double-Stranded

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Discovery

Share to Phthalazines

Share to Piperazines

Share to Poly (ADP-Ribose) Polymerase-1

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Poly(ADP-ribose) Polymerases

Source

Identifiers

PMID: 26384693
DOI: 10.1016/j.bulcan.2015.07.012

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].PMID 26384693Read ↗

[Cancer therapy by PARP inhibitors].Semantic proximity Read ↗

An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer TherapySemantic proximity Read ↗

PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor ResistanceSemantic proximity Read ↗

PARP inhibitors in cancer therapy: an updateSemantic proximity Read ↗

Inhibition of poly(ADP-ribosyl)ation in cancer: Old and new paradigms revisitedSemantic proximity Read ↗

The Emerging Role of Poly(ADP-Ribose) Polymerase Inhibitors in Cancer TreatmentSemantic proximity Read ↗

Poly (ADP-ribose) polymerase inhibitors in cancer therapySemantic proximity Read ↗

Current Development of Clinical Inhibitors of Poly(ADP-Ribose) Polymerase in OncologySemantic proximity Read ↗

PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targetingSemantic proximity Read ↗

The PARP Enzyme Family and the Hallmarks of Cancer Part 2: Hallmarks Related to Cancer Host InteractionsSemantic proximity Read ↗

Poly (ADP-ribose) polymerase (PARP) as target for the treatment of epithelial ovarian cancer: what to know.Semantic proximity Read ↗

[PARP inhibitors--theoretical basis and clinical application].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.